Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Reiterates Neutral Rating on Acadia Healthcare (ACHC)
-
Cantor Fitzgerald Reiterates Neutral Rating on Universal Health Services (UHS)
-
Cantor Fitzgerald Reiterates Overweight Rating on Tenet Healthcare (THC)
-
Cantor Fitzgerald Reiterates Overweight Rating on Klaviyo Inc (KVYO)
-
Cantor Fitzgerald Reiterates Overweight Rating on Eupraxia Pharmaceuticals (EPRX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Oranogenesis Holdings (ORGO)
-
Cantor Fitzgerald Reiterates Overweight Rating on Precigen Inc. (PGEN)
-
Cantor Fitzgerald Reiterates Overweight Rating on Crinetics (CRNX)
-
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC)
-
Cantor Fitzgerald hires Segouin, Goel in tech dealmaking push
-
uniQure BV (QURE) PT Raised to $80 at Cantor Fitzgerald
-
uniQure BV (QURE) PT Raised to $80 at Cantor Fitzgerald
-
Drugs Made In America Acquisition II prices $500 million IPO at $10 per unit
-
Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering
-
Cantor Fitzgerald Upgrades Amentum Holdings Inc. (AMTM) to Overweight
-
Stroud Resources Ltd Announces Appointment of Director and Issuance of Stock Options
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $50 at Cantor Fitzgerald
-
Fermi America™ Announces Launch of Initial Public Offering
-
Vox prices $55 million public offering at $3.70 per share
-
Vox Announces Pricing of $55 Million Underwritten Public Offering of Common Shares
-
Eupraxia Pharmaceuticals closes $80.5 million public offering
-
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
-
Cantor Fitzgerald Reiterates Overweight Rating on Cabaletta Bio Inc. (CABA)
-
SPS Commerce (SPSC) PT Lowered to $135 at Cantor Fitzgerald
-
Micron Technology (MU) PT Raised to $200 at Cantor Fitzgerald
-
MercadoLibre (MELI) PT Raised to $2,900 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Neutral Rating on Alphabet (GOOGL)
-
Lucid Group Inc. (LCID) PT Raised to $26 at Cantor Fitzgerald
-
Vox Royalty acquires $57.5 million global gold portfolio
-
Vox Royalty Announces Agreement to Acquire Transformational Global Gold Portfolio, Overnight Marketed Offering of Common Shares and Expanded Revolving Credit Facility
-
Brera Holdings PLC (NASDAQ: BREA) Closes ~USD $300 Million PIPE Financing
-
BioFuture™ 2025 Explores the Next Era of Innovation, Policy, and Investment in Biopharma
-
Cantor Fitzgerald Reiterates Overweight Rating on Alector Inc. (ALEC)
-
Cantor Fitzgerald Reiterates Overweight Rating on Firefly Aerospace Inc (FLY)
-
Cantor Fitzgerald Reiterates Overweight Rating on Crinetics (CRNX)
-
Cantor Fitzgerald Reiterates Neutral Rating on Marti Technologies (MRT)
-
Eupraxia Pharmaceuticals prices $70 million public offering at $5.50 per share
-
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
-
Eupraxia Pharmaceuticals announces proposed public offering of common shares
-
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares
-
Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings
-
Strive agrees to acquire Semler Scientific in all-stock deal
-
Strive, Inc. (Nasdaq: ASST) and Semler Scientific, Inc. (Nasdaq: SMLR) Announce Bitcoin Treasury Merger in All-Stock Transaction
-
SunPower to acquire Sunder Energy for $40M cash plus shares
-
SPWR to Acquire Sunder Energy to Gain U.S. No. 5 Spot
-
Cantor Fitzgerald Starts CytomX Therapeutics (CTMX) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on Rocket Pharmaceuticals (RCKT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
-
Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Solid Biosciences (SLDB)
